IQVIA (NYSE:IQV) Issues Earnings Results, Misses Expectations By $0.21 EPS

IQVIA (NYSE:IQV) posted its earnings results on Thursday. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21), Zacks reports. IQVIA had a net margin of 9.17% and a return on equity of 28.17%. IQVIA updated its FY 2025 guidance to 11.700-12.100 EPS.

IQVIA Stock Performance

NYSE IQV traded down $2.81 on Friday, hitting $207.15. 363,646 shares of the company traded hands, compared to its average volume of 1,385,062. The company has a market capitalization of $37.60 billion, a price-to-earnings ratio of 27.19, a P/E/G ratio of 2.15 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The business’s 50 day moving average price is $200.53 and its 200-day moving average price is $219.80. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on IQV shares. Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Morgan Stanley decreased their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $252.39.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.